Company news: Eli Lilly and Novartis

Share this article:

Eli Lilly is expanding its Indiana insulin manufacturing operations, marking the first expansion of the company's Indianapolis sites in more than twenty years. The company will provide more details Thursday, but noted in a statement that the new capacity is to meet US demand. The site will make insulin cartridges.

Novartis continues to focus on making Singapore its biotech and manufacturing hub. The company announced Wednesday that it was investing more than $500 million in building a manufacturing facility that will focus on drugs based on cell culture technology. The company said in a statement it expects work to wrap by 2016, and the site will be able to scale up or down to handle a variety of production volumes.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.